【摘要】 近年来，乳腺癌已成为威胁女性生命的最常见的恶性肿瘤之一。由于对乳腺癌分子分型的研究逐渐深入，治疗也越来越个体化。三阴性乳腺癌因其独特的生物学特征及较差的预后受到学术界广泛的关注，而三阳性乳腺癌（triple positive breast cancer,TPBC）因为其独特的病理特点，对化疗、内分泌治疗、靶向治疗均敏感，理论上联合治疗将获得更好的治疗效果，但是临床上发现预后未达预期，原因与其复杂的耐药机制有关，本文对TPBC耐药机制及其最新治疗进展做一综述。更多还原

【Abstract】 In recent years, breast cancer has become one of the most common malignant tumors threatening women’s lives. As the research on the molecular classification of breast cancer is gradually deepening, the treatment is becoming more and more individualized.Triple negative breast cancer has attracted extensive attention due to its unique biological characteristics and poor prognosis. Triple positive breast cancer(TPBC) is sensitive to chemotherapy, endocrine therapy and targeted therapy because of its special pathology.Theoretically, the combination therapy will achieve better therapeutic effect, but the prognosis is not as expected in clinical practice, which is related to the complex drug resistance mechanism. This article reviews the mechanisms of TPBC resistance and the latest treatment progression.更多还原